TransMedics Group (NASDAQ:TMDX) Trading Up 4.5% on Insider Buying Activity

Key Points

• TransMedics shares rose 4.5% to about $89.71 after director David Weill bought 1,336 shares for roughly $109,058, increasing his stake by 8.87%.
• Analyst sentiment is mixed: six analysts rate the stock Buy, six Hold, and one Sell, resulting in an overall “Hold” rating and an average price target of $124.18.
• The company’s latest quarterly revenue rose 20.7% year over year to $189.95 million, beating estimates, although adjusted earnings of $0.44 per share fell short of the $0.50 consensus forecast.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s share price rose 4.5% on Tuesday following insider buying activity. The company traded as high as $89.15 and last traded at $89.7060. 308,922 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 1,029,492 shares. The stock had previously closed at $85.86.

Specifically, Director David Weill acquired 1,336 shares of the business's stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. Piper Sandler reaffirmed an "overweight" rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Stifel Nicolaus upped their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a research report on Thursday, June 18th. UBS Group cut their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 5th. Finally, Needham & Company LLC reiterated a "buy" rating on shares of TransMedics Group in a report on Friday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $124.18.

TransMedics Group Price Performance

The firm has a market cap of $3.12 billion, a P/E ratio of 23.00, a PEG ratio of 1.13 and a beta of 1.90. The business's fifty day simple moving average is $82.29 and its 200-day simple moving average is $89.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million during the quarter, compared to analysts' expectations of $184.00 million. During the same quarter last year, the firm posted $0.92 earnings per share. TransMedics Group's revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Ascentis Independent Advisors acquired a new stake in TransMedics Group during the 1st quarter worth about $30,000. North Star Investment Management Corp. acquired a new position in shares of TransMedics Group in the 1st quarter valued at $30,000. Hantz Financial Services Inc. boosted its holdings in TransMedics Group by 196.2% during the fourth quarter. Hantz Financial Services Inc. now owns 311 shares of the company's stock worth $38,000 after buying an additional 206 shares in the last quarter. Titan Wealth CI Ltd purchased a new position in shares of TransMedics Group in the 4th quarter valued at about $40,000. Finally, Silvant Capital Management LLC purchased a new position in shares of TransMedics Group during the 2nd quarter valued at approximately $26,000. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.